

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF
KATERINA LEFOTHERIS, ET AL.

APPLICATION NO: **10/696178**

FILED: **10/29/2003**

FOR: **NP TITLE - METHODS OF TREATING P38 KINASE-ASSOCIATED
CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE
INHIBITORS**

**DIV TITLE - METHODS OF TREATING P38 KINASE-ASSOCIATED
CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS**

ART UNIT: **1616**

EXAMINER: **PRYOR, ALTON NATHANIEL**

Filed via EFS

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the reference cited on the attached form(s) PTO-1449.

The reference was cited in a Foreign Office Action in a corresponding Indian application. A copy of the reference is enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that the reference was considered by returning a copy of the initialed PTO 1449 form(s) and charge the appropriate fee under §1.17 (p) to Deposit Account 19-3880 in the name of Bristol-Myers Squibb Company.

Certificate under 37 C.F.R. §1.97(e)(1)

I, the undersigned attorney, hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000

Date: January 31, 2007

/joseph c. wang/
Joseph C. Wang
Attorney for Applicant
Reg. No. 44,391
Phone: 609-252-4931